ºÚÁϲ»´òìÈ

Institution: ºÚÁϲ»´òìÈ
Meeting Date: April 28, 2026
Meeting Time: 1:00 PM-3:00 PM
Meeting Type: Hybrid Meeting - ROOM 2200A Building IRP1 and Zoom Platform
IBC Members Present:
.
Lesley Greene (IBC Chair)
Michael Stacey (IBC Vice Chair)
Bruce Finlay (IBC Member/BSO)
Shawn Sarauw (IBC Member/EHS)
Erin Purcell (IBC Member)
Wayne Hynes (IBC Alternate Member/Animal Expert)
Danielle Dady (non-Affiliated Member)
Megan Scott (non-Affiliated Member)
Quorum: 7 members and 1 Alternate Member are present fulfilling quorum requirement.
Other Individuals in Attendance:
Srivenkat Kosuri (Manager Compliance)
Call to Order: The IBC Chair called the meeting to order at 1:03 PM
Conflict of Interest: No conflicts declared.
Review & Approval of previous meeting minutes:
March 31, 2026, meeting minutes were approved unanimously as is.
Review of Prior Business: None

New IBC Registrations:
1. PI Name: Alvin Holder, PhD
Reference Number/Title: [2413845-1/26-007] In Vitro Cytotoxicity of Inorganic Pharmaceuticals and Natural Products against Triple Negative Breast Cancer
NIH Guidelines Section: N/A
Risk Assessment and Discussion:
This submission of new project has received full committee review for risk assessment. The IBC requested a minor modification and a designated member review for final approval after modifications are completed.
Training:
As per Guidelines, laboratory biosafety safety training and bloodborne pathogen safety training for laboratory staff were completed.
Occupational Health Representative review (if applicable):
N/A
Biosafety Level Assignment:
BSL1 and BSL2.
IBC Vote: IBC voted requiring minor modifications and DMR for final approval.
Total = 7; For = 7; Opposed = 0; Abstained = 0
New IBC Registration approvals via DMR after revision:
1. PI Name: Gymama Slaughter, PhD
Reference Number/Title: [[1749811-11/26-006] G. Xylinus Culture
NIH Guidelines Section: N/A
Risk Assessment and Discussion:
This submission of new project has received DMR review for risk assessment after modifications and final approval given.
Training:
As per Guidelines, laboratory biosafety safety training and bloodborne pathogen safety training for laboratory staff were completed.
Occupational Health Representative review (if applicable):
N/A
Biosafety Level Assignment:
BSL1 and BSL2.

IBC Vote: IBC voted via DMR for final approval.
Total = 5; For = 5; Opposed = 0; Abstained = 0
2. PI Name: Rachel Childs, PhD
Reference Number/Title: [[2420250-2/26-006] MLS Summer Immersion Program
NIH Guidelines Section: N/A
Risk Assessment and Discussion:
This submission of new project has received DMR review for risk assessment after modifications and final approval given.
Training:
As per Guidelines, laboratory biosafety safety training and bloodborne pathogen safety training for laboratory staff were completed.
Occupational Health Representative review (if applicable):
N/A
Biosafety Level Assignment:
BSL1 and BSL2.
IBC Vote: IBC voted via DMR for final approval.
Total = 5; For = 5; Opposed = 0; Abstained = 0
Annual Reviews, and Closures of Protocols
1. PI Name: Michelle King, PhD
Reference Number/Title: [2029445-8/23-002] 151 class
NIH Guidelines Section: N/A
Risk Assessment and Discussion:
The committee reviewed risk assessment and approved the protocol to continue.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2
IBC Vote

Total = 5; For = 5; Opposed = 0; Abstained = 0.
2. PI Name: Michelle King, PhD
Reference Number/Title: [2029438-9/23-002] Bio 317 class
NIH Guidelines Section: N/A
Risk Assessment and Discussion:
The committee reviewed risk assessment and approved the protocol to continue.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2
IBC Vote
Total = 5; For = 5; Opposed = 0; Abstained = 0.
3. PI Name: Michelle King, PhD
Reference Number/Title: [2029432-6/23-004] 380-381 class
NIH Guidelines Section: N/A
Risk Assessment and Discussion:
The committee reviewed risk assessment and approved the protocol to continue.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2
IBC Vote
Total = 5; For = 5; Opposed = 0; Abstained = 0.
4. PI Name: Erin Purcell, PhD
Reference Number/Title: [1848237-8]/22-001] Inhibition of bacterial strains associated with vaginal dysbiosis

Risk Assessment and Discussion:
The committee approved the protocol closure.
IBC Vote
Total = 5; For = 5, Opposed = 0; Abstained = 0.
Amendments/Modifications:
1. PI Name: Lisa Shollenberger, PhD
Reference Number/Title: [1822943-10/21-014] BIOL 440/540 Immunological Methods
Risk Assessment and Discussion:
The committee reviewed risk assessment and approved the amendment to protocol.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2
IBC Vote:
Total = 5; For = 5; Opposed = 0; Abstained = 0.
Administrative Business (items approved since last meeting)
1. PI Name: Lesley Greene, PhD
Reference Number/Title: [2406804-2/26-001] Biochemistry and Genomics Research
Risk Assessment and Discussion:
Administrative approval of adding Chris Speckman to the protocol. through the amendment.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2
IBC Vote: N/A

2. PI Name: Lesley Greene, PhD
Reference Number/Title: [2406804-2/26-001] Biochemistry and Genomics Research
Risk Assessment and Discussion:
Adminrative approval of adding Alondra Rodriquez to the protocol. through the amendment.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2
IBC Vote: N/A
New Business/Additional Topics: None
Review of Incidents: None
Inspections/Ongoing Oversight:
Public Comments (If Any): None
Adjournment: The IBC Chair moved to adjourn the meeting at 1.25 PM.
The next meeting is scheduled for May 26, 2026, at 1 PM via a hybrid meeting.

Institution: ºÚÁϲ»´òìÈ
Meeting Date: March 31, 2026
Meeting Time: 1:00 PM-3:00 PM
Meeting Type: Hybrid Meeting - ROOM 2200A Building IRP1 and Zoom Platform
IBC Members Present:.
Lesley Greene (IBC Chair)
Michael Stacey (IBC Vice Chair)
Bruce Finlay (IBC Member/BSO)
Shawn Sarauw (IBC Member/EHS)
Erin Purcell (IBC Member)
Wayne Hynes (IBC Alternate Member/Animal Expert)
Danielle Dady (non-Affiliated Member)
Megan Scott (non-Affiliated Member)
Quorum: 7 members and 1 Alternate Member are resent fulfilling quorum requirement.
Other Individuals in Attendance:
Srivenkat Kosuri (Manager Compliance)
Dr. Rachel Childs
Call to Order: The IBC Chair called the meeting to order at 1:05 PM
Conflict of Interest: No other conflicts declared.
Review & Approval of previous meeting minutes:
February 24, 2026, meeting minutes were approved unanimously as is.
Review of Prior Business: None

New IBC Registrations:
1. PI Name: Rachel Childs, Ph.D
Reference Number/Title: [2420250-1/26-005] MLS Summer Immersion Program
NIH Guidelines Section: N/A
Risk Assessment and Discussion:
This submission of new project has received full committee review for risk assessment. The IBC requested a minor modifications and a designated member review for final approval after modifications are completed.
Training:
As per Guidelines, laboratory biosafety safety training and bloodborne pathogen safety training for laboratory staff were completed.
Occupational Health Representative review (if applicable):
N/A
Biosafety Level Assignment:
BSL1 and BSL2.
IBC Vote: IBC voted requiring minor modifications and DMR for final approval.
Total = 7; For = 7; Opposed = 0; Abstained = 0
New IBC Registration approvals via DMR after revision:
1. PI Name: Harold Riethman, Ph.D
Reference Number/Title: [2409401-1/26-002] Telomere Regulation-2026
Final approval given after DMR
2. PI Name: Laura Grieneisen, Ph.D
Reference Number/Title: [2412872-1/26-004] The lemur gut microbiome
Final approval given after DMR.
3. PI Name: Leryn Reynolds, Ph.D.
Reference Number/Title: 2406749-2/26-003] NEXCOM-WIRC Wellness Event
Final approval given after DMR.

Continuing Reviews, and Closures of Protocols
1. PI Name: Nancy Xu, PhD.
Reference Number/Title: [1853953-8/22-002] Study of Transport and Efflux Function of Single Living Bacterial Cells Using Single Nanoparticle Optics.
NIH Guidelines Section: Section III-F
Risk Assessment and Discussion:
The committee reviewed risk assessment and approved the protocol to continue.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2
IBC Vote
Total = 5; For = 5, Opposed = 0; Abstained = 0.
2. PI Name: Patrick Sachs, PhD
Reference Number/Title: [1864626-7/22-006] Identification of Cancer Biomarkers in the Urine of Firefighters exposed to toxic combustion by-products and their Correlation with Chemical Markers of Exposure Electric Pulses
NIH Guidelines Section: Section III-F
Risk Assessment and Discussion:
The committee reviewed risk assessment and approved the protocol to continue.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2
IBC Vote
Total = 5; For = 5; Opposed = 0; Abstained = 0.
3. PI Name: Rishi Drolia, PhD
Reference Number/Title: [2118787-7/23-024] Listeria Pathogenesis

NIH Guidelines Section: Section III-F
Risk Assessment and Discussion:
The committee approved the protocol closure.
Training:
N/A
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment: N/A
IBC Vote
Total = 5; For = 5; Opposed = 0; Abstained = 0.
Amendments/Modifications:
1. PI Name: Olga Pakhomova, PhD
Reference Number/Title: [1931693-8/22-010] PRIMARY EFFECTS OF PUSED ELECTRIC FIELDS IN MEMBRANES AND MECHANISMS OF THE MEMBRANE INJURY AND RECOVERY
Risk Assessment and Discussion:
The committee reviewed risk assessment and approved the amendment to protocol.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2
IBC Vote:
Total = 5; For = 5; Opposed = 0; Abstained = 0.
2. PI Name: James Lee, PhD
Reference Number/Title: [2212354-11/24-011] GE Microbials and Cells Biosafety Assessment Research
NIH Guidelines Section: Section III-F
Risk Assessment and Discussion:
The committee reviewed risk assessment and approved the amendment to protocol.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety

training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2
IBC Vote:
Total = 5; For = 5; Opposed = 0; Abstained = 0.
Administrative Business (items approved since last meeting)
1. PI Name: Mohamadmahdi Samandari, PhD
Reference Number/Title: [2356139-3/25-009] In situ formed microneedle-like depots for spatiotemporally controlled drug delivery
Risk Assessment and Discussion:
Administrative approval of adding new personnel to the protocol. through the amendment.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2
IBC Vote:
N/A
2. PI Name: Rishi Drolia, PhD
Reference Number/Title: [2118787-6]/23-024 Listeria Pathogenesis
Risk Assessment and Discussion:
Administrative approval of adding new personnel to the protocol through the amendment.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2
IBC Vote:

N/A
New Business/Additional Topics: None
Review of Incidents: None
Inspections/Ongoing Oversight:
Public Comments (If Any): None
Adjournment: The IBC Chair moved to adjourn the meeting at 2:15 PM.
The next meeting is scheduled for March 31, 2026, at 1 PM via a hybrid meeting.

Institution: ºÚÁϲ»´òìÈ
Meeting Date: February 24, 2026
Meeting Time: 1:00 PM-3:00 PM
Meeting Type: Hybrid Meeting - ROOM 2200A Building IRP1 and Zoom Platform
IBC Members Present:
.
Lesley Greene (IBC Chair)
Michael Stacey (IBC Vice Chair)
Bruce Finlay (IBC Member/BSO)
Erin Purcell (IBC Member)
Wayne Hynes (IBC Alternate Member/Animal Expert)
Danielle Dady (non-Affiliated Member)
Quorum: 6 members are resent fulfilling quorum requirement.
Other Individuals in Attendance:
Srivenkat Kosuri (Manager Compliance)
Call to Order: The IBC Chair called the meeting to order at 1:05 PM
Conflict of Interest: No other conflicts declared.
Review & Approval of previous meeting minutes:
January 27, 2026, meeting minutes were approved unanimously as is.
Review of Prior Business: None

New IBC Registrations:
1. PI Name: Leryn Reynolds, Ph.D
Reference Number/Title: [2406749-1/26-003] NEXCOM-WIRC Wellness Event
NIH Guidelines Section: N/A
Risk Assessment and Discussion:
This submission of new project has received full committee review for risk assessment. The IBC requested a minor modification.
Training:
As per Guidelines, laboratory biosafety safety training and bloodborne pathogen safety training for laboratory staff were completed.
Occupational Health Representative review (if applicable):
N/A
Biosafety Level Assignment:
BSL1 and BSL2.
IBC Vote: IBC voted requiring minor modificwereations and DMR for final approval.
Total = 6; For = 6; Opposed = 0; Abstained = 0

2. PI Name: Harold Riethman, Ph.D
Reference Number/Title: [2409401-1/26-002] Telomere Regulation-2026
NIH Guidelines Section: N/A
Risk Assessment and Discussion:
This submission of new project has received full committee review for risk assessment. The IBC requested a minor modification.
Training:
As per Guidelines, laboratory biosafety safety training and bloodborne pathogen safety training for laboratory staff were completed.
Occupational Health Representative review (if applicable):
N/A
Biosafety Level Assignment:
BSL1 and BSL2.
IBC Vote: IBC voted requiring minor modifications and DMR for final approval.
Total = 6; For = 6; Opposed = 0; Abstained = 0

3. PI Name: Laura Grieneisen, Ph.D
Reference Number/Title: [2412872-1/26-004] The lemur gut microbiome
NIH Guidelines Section: N/A
Risk Assessment and Discussion:
This submission of new project has received full committee review for risk assessment. The IBC requested a minor modification.
Training:
As per Guidelines, laboratory biosafety safety training and bloodborne pathogen safety training for laboratory staff were completed.
Occupational Health Representative review (if applicable):
N/A
Biosafety Level Assignment:
BSL1 and BSL2.
IBC Vote: IBC voted requiring minor modifications and DMR for final approval.
Total = 6; For = 6; Opposed = 0; Abstained = 0

New IBC Registration approvals via DMR after revision:
None
Continuing Reviews, and Closures of Protocols
1. PI Name: Emilia Oleszak, Ph.D
Reference Number/Title: [1997607-8/23-001] Epigenetic determinants of nuclear membrane electro-modulation.
NIH Guidelines Section: Section III-F
Risk Assessment and Discussion:
The committee reviewed risk assessment and approved the protocol to continue.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2
IBC Vote
Total = 6; For = 6; Opposed = 0; Abstained = 0.
2. PI Name: Pavel Solopov, DVM, PhD
Reference Number/Title: [2277723-15/25-001] Enhanced Gelonin Delivery to Esophageal Squamous Cell Carcinoma Using
Electric PulsesNIH Guidelines Section: Section III-F
Risk Assessment and Discussion:
The committee reviewed risk assessment and approved the protocol to continue.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2
IBC Vote
Total = 6; For = 6; Opposed = 0; Abstained = 0.

3. PI Name: Harold Riethman, PhD
Reference Number/Title: [1683023-15/2--007] Telomere regulation
NIH Guidelines Section: Section III-F
Risk Assessment and Discussion:
The committee approved the protocol closure.
Training:
N/A
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment: N/A
IBC Vote
Total = 6; For = 6; Opposed = 0; Abstained = 0.
4. PI Name: Stephen J Beebe, PhD
Reference Number/Title: 1790522-9/21-010] Effects of NPS on Mitochondrial Function
Electric PulsesNIH Guidelines Section: Section III-F
Risk Assessment and Discussion:
The committee reviewed risk assessment and approved the protocol to continue.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2
IBC Vote
Total = 6; For = 6; Opposed = 0; Abstained = 0.
5. PI Name: Isaura Simoes, PhD
Reference Number/Title: [2151889-5/24-005] IBC Registration Form_2024
Electric PulsesNIH Guidelines Section: Section III-F
Risk Assessment and Discussion:

The committee reviewed risk assessment and approved the protocol to continue.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2
IBC Vote
Total = 6; For = 6; Opposed = 0; Abstained = 0.
Amendments/Modifications:
1. PI Name: Rishi Drolia, PhD
Reference Number/Title: [2118787-5/23-024] Listeria Pathogenesis
NIH Guidelines Section: Section III-F
Risk Assessment and Discussion:
The committee reviewed risk assessment and approved the amendment to protocol.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2
IBC Vote:
Total = 6; For = 6; Opposed = 0; Abstained = 0.
2. PI Name: James Lee, PhD
Reference Number/Title: [2212354-11/24-011] GE Microbials and Cells Biosafety Assessment Research
NIH Guidelines Section: Section III-F
Risk Assessment and Discussion:
The committee reviewed risk assessment and approved the amendment to protocol.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.

Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2
IBC Vote:
Total = 6; For = 6; Opposed = 0; Abstained = 0.
Administrative Business (items approved since last meeting)
1. PI Name: Patrick Sachs, PhD
Reference Number/Title: [2187930-5/24-009] Isolation/generation, culture, and transplantation of Cell lines/ECMs
NIH Guidelines Section: Section III-F
Risk Assessment and Discussion:
Administrative approval of adding new personnel to the protocol. through the amendment.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2
IBC Vote:
N/A
2. PI Name: Patrick Wilson, PhD
Reference Number/Title: [2391409-3/25-014] IBC Protocol for “Associations Between Changes In Body Composition And Measures Of Hydration Among Individuals Intentionally Losing Weight.
NIH Guidelines Section: Section III-F
Risk Assessment and Discussion:
Administrative approval of adding new personnel to the protocol through the amendment.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2

IBC Vote:
N/A
3. PI Name: John Catravas,, PhD
Reference Number/Title: [2333110-3/25-003] Developing KVX-053, a PTP4A3 Targeted Small Molecule Inhibitor for Acute
Lung InjuryNIH Guidelines Section: Section III-F
Risk Assessment and Discussion:
Administrative approval of adding new personnel to the protocol through the amendment.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2
IBC Vote:
N/A
New Business/Additional Topics: A request from IBC administration & BSO to discuss and establish guidelines for BSL2+
procedures and requirements for protocol that require BSL2+ procedures
Review of Incidents: None
Inspections/Ongoing Oversight:
Public Comments (If Any): None
Adjournment: The IBC Chair moved to adjourn the meeting at 2:15 PM.
The next meeting is scheduled for March 31, 2026, at 1 PM via a hybrid meeting.

Institution: ºÚÁϲ»´òìÈ
Meeting Date: January 27, 2026
Meeting Time: 1:00 PM-3:00 PM
Meeting Type: Hybrid Meeting - ROOM 2200A Building IRP1 and Zoom Platform
IBC Members Present:
.
Lesley Greene (IBC Chair)
Michael Stacey (IBC Vice Chair)
Bruce Finlay (IBC Member/BSO)
Erin Purcell (IBC Member)
Patrick Sachs (IBC Member)
Shawn Sarauw (IBC Member)
Wayne Hynes (IBC Alternate Member/Animal Expert)
Danielle Dady (non-Affiliated Member)
Quorum: Present
Other Individuals in Attendance:
Srivenkat Kosuri (Manager Compliance)
Call to Order: The IBC Chair called the meeting to order at 1:05 PM
Conflict of Interest: Lesley Greene declared a conflict and recused from deliberations and voting on her protocol. No other conflicts declared.
Review & Approval of previous meeting minutes:
December 16, 2025, meeting minutes are approved unanimously after spelling mistake of a PI is corrected.
Review of Prior Business: None

New IBC Registrations:
1. PI Name: Lesley Greene
Reference Number/Title: [2406804-1/26-001] Biochemistry and Genomics Research
NIH Guidelines Section: N/A
Risk Assessment and Discussion:
This submission of new project has received full committee review for risk assessment. The IBC requested a minor modification of BSL-2 classification for one organism and approved.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
N/A
Biosafety Level Assignment:
BSL1 and BSL2.
IBC Vote:
Total = 7; For = 7; Opposed = 0; Abstained = 0

Institution: ºÚÁϲ»´òìÈ
Meeting Date: July 29, 2025
Meeting Time: 1:00 PM-3:00 PM
Meeting Type: Hybrid Meeting - ROOM 2200A Building IRP1 and Zoom Platform
IBC Members Present:
.
Lesley Greene (IBC Chair)
Michael Stacey (IBC Vice-Chair)
Bruce Finlay (IBC Member/BSO)
Erin Purcell (IBC Member)
Patrick Sachs (IBC Member)
Shawn Sarauw (IBC Member)
Wayne Hynes (IBC Member/Animal Expert)
Danielle Dady (Non-Affiliated Member)
Megan Scott (Non-Affiliated Member)
Quorum: Present
Other Individuals in Attendance:
Srivenkat Kosuri (Manager Compliance)
Call to Order: The IBC Chair called the meeting to order at 1:05 PM
Conflict of Interest: Conflict declared and recused from deliberations.
Please see under votes for each protocol for details.
Review & Approval of previous meeting minutes:
June 2025, meeting minutes are approved as written unanimously.
Review of Prior Business: None
- 2 - Generated on IRBNet
New IBC Registrations
PI Name: David Gauthier, Ph.D.
Reference Number/Title:
[2334120-1/25-005]/ BIOL454/455 class IBC
NIH Guidelines Section: N/A
Risk Assessment and Discussion:
This submission of new project has received full committee review for risk assessment. After the required modifications, and it was approved.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
N/A
Biosafety Level Assignment:
BSL1
IBC Vote:
This new protocol submission has received full committee review and approval.
Total = 9; For = 9; Opposed = 0; Abstained = 0; Recused =0.

Institution: ºÚÁϲ»´òìÈ
Meeting Date: August 26, 2025
Meeting Time: 1:00 PM-3:34 PM
Meeting Type: Zoom Meeting on Zoom Platform
IBC Members Present:
.
Lesley Greene (IBC Chair)
Michael Stacey (IBC Vice-Chair)
Bruce Finlay (IBC Member/BSO)
Erin Purcell (IBC Member)
Patrick Sachs (IBC Member)
Shawn Sarauw (IBC Member)
Lisa Shollenberger (IBC Member/Animal Expert)
Wayne Hynes (IBC Alternate Member/Animal Expert)
Danielle Dady (Non-Affiliated Member)
Megan Scott (Non-Affiliated Member)
Quorum: Five members are required to conduct business. 9 voting members were present at the start of the meeting. Attendees were reminded that they are required to disclose conflicts of interest with applications being reviewed.
Other Individuals/Guests in Attendance:
Srivenkat Kosuri (Manager Compliance)
Holly Gaff (PI)
Mahamadmahdi Samandari (PI)
Call to Order: The IBC Chair called the meeting to order at 1:05 PM
Conflict of Interest: Attendees were reminded that they are required to disclose conflicts of interest with applications being reviewed. Conflict declared and recused from voting.
Please see under votes for each protocol for details.
Review & Approval of previous meeting minutes:
July 2025 IBC meeting minutes are approved as written unanimously.
Review of Prior Business: None
- 2 - Generated on IRBNet
New IBC Registrations
PI Name: Holly Gaff, Ph.D.
Reference Number/Title:
[2353785-3/25-008] Small Mammal Museum Specimen Preservation.
NIH Guidelines Section: N/A
Risk Assessment and Discussion:
This submission of new project has received full committee review for risk assessment.
The overall goal of this project is to create much needed natural history museum specimens out of deceased small mammals. These animals are from donations, accidental deaths. The work will be archived in either the ºÚÁϲ»´òìÈ natural history collections or donated to other collections around the world. The project will involve training students in the techniques for optimal museum collections.
The IBC required minor modifications and a designated member review after modification for an approval.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
N/A
Biosafety Level Assignment:
BSL1
IBC Vote:
This new protocol submission has received full committee review and approval after designated member review. Dr. Purcell not present.
Total = 8; For = 8; Opposed = 0; Abstained = 0; Recused =0.

Institution: ºÚÁϲ»´òìÈ
Meeting Date: September 30, 2025
Meeting Time: 1:00 PM-1:32 PM
Meeting Type: Zoom Meeting on Zoom Platform
IBC Members Present:
.
Lesley Greene (IBC Chair)
Bruce Finlay (IBC Member/BSO)
Erin Purcell (IBC Member)
Patrick Sachs (IBC Member)
Shawn Sarauw (IBC Member)
Lisa Shollenberger (IBC Member/Animal Expert)
Wayne Hynes (IBC Alternate Member/Animal Expert)
Danielle Dady (Non-Affiliated Member)
Quorum: Five members are required to conduct business. 7 voting members were present at the start of the meeting.
Other Individuals/Guests in Attendance:
Srivenkat Kosuri (Manager Compliance)
Call to Order: The IBC Chair called the meeting to order at 1:02 PM
Conflict of Interest: Attendees were reminded that they are required to disclose conflicts of interest with applications being reviewed.
Review & Approval of previous meeting minutes:
After corrections on attendance numbers of voting members, August 2025 IBC meeting minutes were approved unanimously.
Review of Prior Business: Final Approval of new protocols after revisions via DMR.
PI Name: Ryan McCann, Ph.D.
Reference Number/Title:
[2354126-1/25-006] ºÚÁϲ»´òìÈ Master of Science of Athletic Training Teaching
Laboratory Registration
- 2 - Generated on IRBNet
PI Name: Mohamadmahdi Samandari, Ph.D.
Reference Number/Title:
[2356139-1/25-009] In situ formed microneedle-like depots for spatiotemporally controlled drug
Delivery
PI Name: Lobat Tayebi, Ph.D.
Reference Number/Title:
[2356438-1/25-011] Pre-vascularization of an Integrated 3D Human Osteo-Mucosal Model
New IBC Registrations
None.
Continuing Review of Protocols, Closures, and Amendments:
None
New Business/Additional Topics: The IBC discussed modifying the Designated Member Review (DMR) by adding additional members. The IBC Chair suggested to have 3 members for DMR that includes BSO and subject matter expert.
Review of Incidents: None
Inspections/Ongoing Oversight: None
Public Comments (If Any): None
Adjournment: The IBC Chair moved to adjourn the meeting at 1:32 PM.
The next meeting scheduled is on October 28, 2025, at 1 PM via a Zoom teleconference..

Institution: ºÚÁϲ»´òìÈ
Meeting Date: October 28, 2025
Meeting Time: 1:00 PM
Meeting Type: Electronic Meeting to approve September 2025 IBC Meeting Minutes.
IBC Members Present:
.
Lesley Greene (IBC Chair)
Stacey Michael (IBC Vice-Chair)
Bruce Finlay (IBC Member/BSO)
Erin Purcell (IBC Member)
Shawn Sarauw (IBC Member)
Lisa Shollenberger (IBC Member/Animal Expert)
Quorum: Five members are required to conduct business. 6 voting members were present at the start of the meeting.
Other Individuals/Guests in Attendance:
Srivenkat Kosuri (Manager Compliance)
Call to Order: The IBC Electronically met to vote to approval of the September 2025 IBC Meeting Minutes.
Conflict of Interest: Attendees were reminded that they are required to disclose conflicts of interest with applications being reviewed.
Review & Approval of previous meeting minutes: Six voting members unanimously voted to approve September 2025 IBC meeting minutes.
Review of Prior Business: Final Approval of new protocols after revisions via DMR.
PI Name: Margie Mulholland, Ph.D.
Reference Number/Title: [2373421-1 - 25-012] Water testing
NIH Guidelines Section: N/A
Risk Assessment and Discussion:
Designated members reviewed risk assessment and approved the modifications of new protocol.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
- 2 - Generated on IRBNet
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1
IBC Vote for minor revisions:
Total = 7; For = 7; Opposed = 0; Abstained = 0; Recused =0
Designated Member Review (DMR)
Total =3; For = 3; Opposed = 0; Abstained = 0; Recused =0
New IBC Registrations
None.
Continuing Review of Protocols, Closures, and Amendments:
PI Name: Venkat Maruthamuthu, Ph.D.
Reference Number/Title: [1819618-23 - 21-013] Study of Adhesion in Mammalian Cells
NIH Guidelines Section: Section III-F
Risk Assessment and Discussion:
The committee reviewed risk assessment and approved the protocol to continue.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1 and BSL2
IBC Vote
Total = 7; For = 7; Opposed = 0; Abstained = 0; Recused =0
PI Name: Lisa Shollenberger, Ph.D.
Reference Number/Title: [1822943-9 - 21-014] BIOL 440/540 Immunological Methods
NIH Guidelines Section: N/A
Risk Assessment and Discussion:
The committee reviewed risk assessment and approved the protocol to continue.
- 3 - Generated on IRBNet
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1
IBC Vote for minor revisions
Total = 7; For = 7; Opposed = 0; Abstained = 0; Recused =0
PI Name: Sage Hawn, Ph.D.
Reference Number/Title: [2104054-11 - 23-017] IBC-Biological Correlates of Trauma-Related Self-Medication Processes
NIH Guidelines Section: N/A
Risk Assessment and Discussion:
The committee reviewed risk assessment and approved the protocol to continue.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
BSL1
IBC Vote
Total = 7; For = 7; Opposed = 0; Abstained = 0; Recused =0
PI Name: Nawarathna, Dharmakeerthi, Ph.D.
Reference Number/Title: [1956206-8 - 22-012] Sensor Development for Biomarker Detection
NIH Guidelines Section: N/A
Risk Assessment and Discussion:
The amendment to add personnel was administratively reviewed and approved.
Training:
As per NIH Guidelines, biosafety, recombinant DNA Guidelines and laboratory safety training for laboratory staff was completed.
Occupational Health Representative review (if applicable):
None required.
Biosafety Level Assignment
- 4 - Generated on IRBNet
BSL1
IBC Vote
N/A
New Business/Additional Topics:
IBC approved unanimously ºÚÁϲ»´òìÈ Lentivirus SOPs .
IBC approved unanimously ºÚÁϲ»´òìÈ SOPs with addition of Designated Member Review of Protocols after minor modification.
Review of Incidents: None
Inspections/Ongoing Oversight: None
Public Comments (If Any): None
Adjournment: The next meeting scheduled is on November 18, 2025, at 1 PM via a Zoom teleconference.

Institution: ºÚÁϲ»´òìÈ Meeting Date: November 18, 2025.
Meeting Time: 1:00 PM-3:00 PM
Meeting Type: Zoom Meeting on Zoom Platform
IBC Members Present:
.
Lesley Greene (IBC Chair) Bruce Finlay (IBC Member/BSO) Shawn Sarauw (IBC Member)
Lisa Shollenberger (IBC Member/Animal Expert) Danielle Dady (Non-Affiliated Member)
Megan Scott (Non-Affiliated Member)
Quorum: Five members are required to conduct business. 6 voting members were present at the start of the meeting.
Other Individuals/Guests in Attendance:
Srivenkat Kosuri (Manager, Compliance)
Call to Order: The IBC Chair called the meeting to order at 1:04 PM
Conflict of Interest: Attendees were reminded that they are required to disclose conflicts of interest with applications being reviewed.
Review & Approval of previous meeting minutes:
After corrections on attendance numbers of voting members, October 2025 IBC meeting minutes were approved unanimously.
- 2 - Generated on IRBNet
Review of New Protocols:
PI Name: Gymama Slaughter, Ph.D.
Reference Number/Title: [1643107-12] Detection of miRNA in human derived samples (serum/plasma from prostate cancer patients)
NIH Guidelines Section: Section III-F
Risk Assessment and Discussion: The committee reviewed risk assessment, requested minor modifications in the protocol and voted for a Designated Member Review after modification for a final approval.
IBC Vote: The committee approved for a DMR after minor modifications are completed.
Total =6; For = 6; Opposed = 0; Abstained = 0; Recused =0
Continuing Review of Protocols, Closures, and Amendments:
PI Name: Nancy Xu, Ph.D.
Reference Number/Title: [975232-7 /22-014] Multiplexing Quantitative Photostable Nanoscopy for Single Live Cell Imaging Project
NIH Guidelines Section: N/A
Assessment and Discussion: The committee reviewed risk assessment and approved the protocol to continue.
Biosafety Level Assignment: BSL-2
IBC Vote This submission has received full committee review and approval.
Total = 6; For =6; Opposed = 0; Abstained = 0; Recused =0
PI Name: Steven Pascal, Ph.D.
Reference Number/Title: [1944784-5/22-011] Pascal Lab proteins and RNA
NIH Guidelines Section: N/A
Assessment and Discussion: The committee reviewed risk assessment and approved the protocol to continue.
Biosafety Level Assignment: BSL-1
IBC Vote This submission has received full committee review and approval.
Total = 6; For =6; Opposed = 0; Abstained = 0; Recused =0
PI Name: David Courson, PhD.
Reference Number/Title: [2094841-4/23-015] Biochemistry Laboratory (CHEM 442/542)
NIH Guidelines Section: N/A
Assessment and Discussion: The committee reviewed risk assessment and approved the protocol to continue.
Biosafety Level Assignment: N/A
IBC Vote This submission has received full committee review and approval.
- 2 - Generated on IRBNet
Total = 6; For =6; Opposed = 0; Abstained = 0; Recused =0
PI Name: Rishi Drolia, Ph.D.
Reference Number/Title: [2145939-2/24-001] BIOL 301 (Spring 2023) Teaching Protocol
NIH Guidelines Section: N/A
Assessment and Discussion: The committee reviewed risk assessment and approved the protocol to continue.
Biosafety Level Assignment: BSL-1
IBC Vote This submission has received full committee review and approval.
Total = 6; For =6; Opposed = 0; Abstained = 0; Recused =0
PI Name: Rishi Drolia, PhD
Reference Number/Title: [2073893-3/23-010] Holding Protocol for Transfer of Biological Materials & Resources from EKU to ºÚÁϲ»´òìÈ
NIH Guidelines Section: N/A
Assessment and Discussion: The committee reviewed risk assessment and approved the protocol to continue.
Biosafety Level Assignment: BSL-2
IBC Vote This submission has received full committee review and approval.
Total = 6; For =6; Opposed = 0; Abstained = 0; Recused =0
PI Name: Rishi Drolia, PhD
Reference Number/Title: [2118789-4/23-023] Mitigating Inflammatory Bowel Disease using Engineered Probiotics.
NIH Guidelines Section: N/A
Assessment and Discussion: The committee reviewed
Biosafety Level Assignment: BSL-2
IBC Vote This submission has received full committee review and approval.
Total = 6; For =6; Opposed = 0; Abstained = 0; Recused =0
PI Name: Nancy Xu, Ph.D.
Reference Number/Title: [975232-7 /22-014] Multiplexing Quantitative Photostable Nanoscopy for Single Live Cell Imaging Project
NIH Guidelines Section: N/A
Assessment and Discussion: The committee reviewed risk assessment and approved the amendment to protocol to continue.
Biosafety Level Assignment: BSL-2
IBC Vote This submission has received full committee review and approval.
Total = 6; For =6; Opposed = 0; Abstained = 0; Recused =0
PI Name: Nancy Xu, Ph.D.
Reference Number/Title: [1853953-7/22-002] Study of Transport and Efflux Function of Single Living Bacterial Cells Using
Single Nanoparticle Optics
PI: Nancy
- 2 - Generated on IRBNet
NIH Guidelines Section: N/A
Assessment and Discussion: The committee reviewed risk assessment and requested NIH rDNA guidelines training for approval
Biosafety Level Assignment: BSL-2
This submission has received full committee review of the amendment and requested training for approval.
PI Name: Patrick Wilson, Ph.D.
Reference Number/Title: [2266949-5/24/018] IBC Protocol for “The impact of different food orders on blood glucose and fuel use at rest
NIH Guidelines Section: N/A
Assessment and Discussion: The committee reviewed risk assessment and approved the protocol to continue.
Biosafety Level Assignment: BSL-2
IBC Vote This submission has received full committee review and approval.
Total = 6; For =6; Opposed = 0; Abstained = 0; Recused =0
PI Name: Ruben Manuel Luciano Colunga Biancatelli, M.D.
Reference Number/Title: [2078554-5] KVX-053 protects endothelial cultures from injury mediated by extracellular vesicle isolated from patients with ARDS
NIH Guidelines Section: N/A
Assessment and Discussion: The committee reviewed risk assessment and approved the protocol to continue.
Biosafety Level Assignment: BSL-2
IBC Vote This submission has received full committee review and approval.
Total = 6; For =6; Opposed = 0; Abstained = 0; Recused =0
PI Name: Patrick Sachs, PhD
Reference Number/Title: [2107098-4/23/022] MDTS 501/401, MDTS 601, MDTS 668
NIH Guidelines Section: N/A
Assessment and Discussion: The committee reviewed risk assessment and approved the protocol to continue.
Biosafety Level Assignment: BSL-1
IBC Vote This submission has received full committee review and approval.
Total = 6; For =6; Opposed = 0; Abstained = 0; Recused =0
- 2 - Generated on IRBNet
Administrative Business (items approved since last meeting)
PI Name: Holly Gaff, PhD
Reference Number/Title: [2353785-5/25-008] Small Mammal Museum Specimen Preservation
Submission Type: Amendment/Modification
Review Type: Administrative Review
Action: Approved
New Business/Additional Topics: None
Review of Incidents: None Inspections/Ongoing Oversight: None Public Comments (If Any): None
Adjournment: The IBC Chair moved to adjourn the meeting at 1:42 PM.
The next meeting scheduled is on December 16 28, 2025, at 1 PM via a Zoom teleconference.

Institution: ºÚÁϲ»´òìÈ
Meeting Date: December 16, 2025
Meeting Time: 1:00 PM
Meeting Type: Electronic Meeting to approve November 2025 IBC Meeting Minutes.
IBC Members Present:
Lesley Greene (IBC Chair)
Bruce Finlay (IBC Member/BSO)
Shawn Sarauw (IBC Member)
Lisa Shollenberger (IBC Member/Animal Expert)
Danielle Dady (Non-Affiliated Member)
Megan Scott (Non-Affiliated Member)
Quorum: Five members are required to conduct business. 6 voting members were present at the start of the meeting.
Other Individuals/Guests in Attendance:
Srivenkat Kosuri (Manager Compliance)
Call to Order: The IBC Electronically met via Zoom Video conferencing call to vote to approval of the December 2025 IBC Meeting Minutes and two new protocols.
Conflict of Interest: Attendees were reminded that they are required to disclose conflicts of interest with applications being reviewed.
Review & Approval of previous meeting minutes: Six voting members unanimously voted to approve November 2025 IBC meeting minutes.
New IBC Registrations
1. Principal Investigator : Patric Wilson PhD
Reference Number/Title: [ 25-014] IBC Protocol for ô€€€Associations Between Changes In Body Composition And
Measures Of Hydration Among Individuals Intentionally Losing Weight.ô€€€
Discussion and Remarks: This submission of rivision of new protocol has received full committee review and
modifications and designated review and approval.
Vote: Total = 5; For = 5; Opposed = 0; Abstained = 0;
2. Principal Investigator: Patric Wilson PhD
Reference Number/Title: [ 25-015] Evaluation of Different Forms of Sodium Bicarbonate on
Performance, Physiology, and Perceptions with High-Intensity Cycling Exerciseô€€€
Discussion and Remarks: This submission of new protocol has received full committee review and
modifications and designated review and approval.
Vote: Total = 5; For = 5; Opposed = 0; Abstained = 0;
Continuing Review of Protocols, Closures, and Amendments:
1. Principal Investigator : David Gauthier, PhD
Reference Number/Title: [1886962-4/22-007] Climate Change Impacts on White Grub Infestations in Largemouth Bass in Back
Bay, Virginia
Discussion and Remarks: This submission of new protocol has received full committee review and approval.
Vote: Total = 5; For = 5; Opposed = 0; Abstained = 0;
2. Principal Investigator: Thomas Campbell, PhD
Reference Number/Title: [1592114-20/21-012] The Effects of Head Impacts on Concussion Assessment Measurements and
Salivary MicroRNA
Discussion and Remarks: This submission of new protocol has received full committee review and approval.
Vote: Total = 5; For = 5; Opposed = 0; Abstained = 0;
3. Principal Investigator: Lisa Shollenberger, PhD
Reference Number/Title: [2195748-5//22-010] Overcoming vaccine failure: biosafety of vaccine vectors
Discussion and Remarks: This submission of new protocol has received full committee review and approval.
Vote: Total = 5; For = 5; Opposed = 0; Abstained = 0;
4. Principal Investigator: Stacie Ringleb, PhD
Reference Number/Title: [1824921-10/21-015] In vitro testing of human and porcine joints and ligaments
Discussion and Remarks: This submission of new protocol has received full committee review and approval.
Vote: Total = 5; For = 5; Opposed = 0; Abstained = 0;
5. Principal Investigator: Gymama Slaughter, PhD
Reference Number/Title: [1643107-13/25-013] Detection of miRNA in human derived samples (serum/plasma from prostate
cancer patients)
Discussion and Remarks: This submission of new protocol has received full committee review, DMR after minor
modifications and approved.
Vote: Total = 5; For = 5; Opposed = 0; Abstained = 0;
6. Principal Investigator: Thomas Campbell, PhD
Reference Number/Title: [1592114-21] The Effects of Head Impacts on Concussion Assessment Measurements and
Salivary MicroRNA
Discussion and Remarks: This submission of amendment has received full committee review, and approved.
Vote: Total = 5; For = 5; Opposed = 0; Abstained = 0;
7. Principal Investigator: Thomas Campbell, PhD
Reference Number/Title: [ 2149416-5/24-003 The relationship between various hydration biomarkers and body composition measures
Discussion and Remarks: This submission of closure has received full committee review, and approved.
Vote: Total = 5; For = 5; Opposed = 0; Abstained = 0;
8. Principal Investigator: Erin Purcelll, PhD
Reference Number/Title: [1756703-16/21-004] Mechanisms of Stress Survival in Gram Positive Bacteria
Discussion and Remarks: This submission of closure has received full committee review, and approved.
Vote: Total = 5; For = 5; Opposed = 0; Abstained = 0;
New Business/Additional Topics:
None
Review of Incidents: None
Inspections/Ongoing Oversight: None
Public Comments (If Any): None
Adjournment: The next meeting scheduled is on January 27, 2026, at 1 PM via a Zoom teleconference.